The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development
Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this link
The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:
- Type of Product Manufactured
- Active Pharmaceutical Ingredients (APIs)
- Finish Drug Formulations (FDFs)
- Type of Type of Formulation
- Solid Formulations
- Oral Liquids
- Injectables
- Others
- Scale of Operation
- Clinical
- Commercial
- Company Size
- Small-sized
- Mid-sized
- Large
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific and Rest of the World
The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Bristol Myers Squibb
- GlaxoSmithKline
- Incyte
- Novartis
- Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Profiles
6. Regional Capability Analysis
7. Likely Partner Analysis
8. Clinical Trial Analysis
9. Capacity Analysis
10. Demand Analysis
11. Make versus Buy Decision Making Framework
12. Microbiome related initiatives of Big Pharmaceutical Players
13. Market Forecast
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and
Microbial Contract Service Providers
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415